The mission of a TrialNet Center is to engage subjects at risk for type 1 diabetes (T1D) in clinical trials to prevent or delay the onset of the disease. TrialNet's importance is emphasized by persistently high rates of nephropathy among people with T1D, despite declines in other microvascular complications and a recently reported increase in mortality among teens with T1D. With a population of 5.5 million, some 20,000 Atlantans have T1D. Thus, there is enormous opportunity to increase number of local TrialNet participants. This Center application proposes a 4-year plan to triple the current rate of TrialNet enrollment by the Emory University team and to improve the retention rate of autoantibody-positive subjects from 67 to 85 percent. These goals will be attained by expanding our recruiting outreach that has focused so far on the Emory pediatric diabetes clinic. We now propose to span all of Atlanta's pediatric endocrinology offices and selected, productive adult endocrinology practices. A history of collaboration among Atlanta's pediatric endocrinologists and the convergence of virtually all of the area's pediatric T1D patients on Children's Healthcare of Atlanta (CHOA) assure us access to virtually every family with an affected child. We further propose a series of office-based recruiting methods to introduce TrialNet to adult endocrinology offices in Atlanta. A greeter will make initial contact with patients visiting their endocrinologis for routine T1D care and facilitate methods to identify potentially interested relatives who will atten a screening event or enter TrialNet through a local laboratory. A custom mobile phone application will be designed to ease the patient's outreach to their family while keeping communications confidential. The greeter will rotate through the offices with a focus point being an off-hours screening event to be held at their physicians office in the coming month. These multi-media events will include educational exhibits/activities constructed by senior biomedical engineering students attending the Georgia Institute of Technology. The events and other TrialNet activities will be supported by a website hosted by Emory Pediatric Endocrinology and CHOA. Retention rates will be improved by implementing a motivational interviewing intervention. The intervention will be launched by completion of a 12-item questionnaire on Survey Monkey both before and after screening results are reported to subjects. It will determine each subject's motivation for participating in TrialNet and explore potential barriers to further activity should they turn out to be autoantibody-positive. After receiving a report of a positive autoantibody, a pediatric psychologist with expertise in motivational interviewing will us the survey information to guide an interview aimed at reducing barriers and encouraging retention in TrialNet. A TrialNet Center at Emory University will bring real growth to TrialNet without impinging on the activities of existing TrialNet Centers. It offers a highly trained staff, collaborations with innovative faculty and private practitioners, the ingenuity of bioengineers at Georgia Tech, and support from the many sites of the Atlanta Clinical and Translational Science Institute.
Type 1 diabetes causes profound health complications and early death for as many as 3 million Americans. The TrialNet consortium aims to find treatments that prevent or delay the onset of type 1 diabetes. This proposal outlines methods for recruiting and retaining eligible participants in TrialNet throughout the Atlanta Metropolitan Service Area.
|Yeo, Lorraine; Woodwyk, Alyssa; Sood, Sanjana et al. (2018) Autoreactive T effector memory differentiation mirrors ? cell function in type 1 diabetes. J Clin Invest 128:3460-3474|
|Redondo, Maria J; Geyer, Susan; Steck, Andrea K et al. (2018) A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. Diabetes Care 41:1887-1894|
|Greenbaum, Carla J; Speake, Cate; Krischer, Jeffrey et al. (2018) Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience. Diabetes 67:1216-1225|
|Redondo, Maria J; Geyer, Susan; Steck, Andrea K et al. (2018) TCF7L2 Genetic Variants Contribute to Phenotypic Heterogeneity of Type 1 Diabetes. Diabetes Care 41:311-317|
|Sosenko, Jay M; Geyer, Susan; Skyler, Jay S et al. (2018) The influence of body mass index and age on C-peptide at the diagnosis of type 1 diabetes in children who participated in the diabetes prevention trial-type 1. Pediatr Diabetes 19:403-409|
|Vecchio, Federica; Lo Buono, Nicola; Stabilini, Angela et al. (2018) Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes. JCI Insight 3:|
|Redondo, Maria J; Steck, Andrea K; Sosenko, Jay et al. (2018) Transcription Factor 7-Like 2 (TCF7L2) Gene Polymorphism and Progression From Single to Multiple Autoantibody Positivity in Individuals at Risk for Type 1 Diabetes. Diabetes Care 41:2480-2486|
|Sanda, Srinath; Type 1 Diabetes TrialNet Study Group (2018) Increasing ICA512 autoantibody titers predict development of abnormal oral glucose tolerance tests. Pediatr Diabetes 19:271-276|
|Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group; Krischer, Jeffrey P; Schatz, Desmond A et al. (2017) Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial. JAMA 318:1891-1902|
|Bosi, Emanuele; Boulware, David C; Becker, Dorothy J et al. (2017) Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives. J Clin Endocrinol Metab 102:2881-2886|
Showing the most recent 10 out of 15 publications